AtriCure (ATRC) Director Reports 5,000-Share Trades and Option Increase

Rhea-AI Filing Summary

Sven Wehrwein, a director of AtriCure, Inc. (ATRC), reported multiple transactions on 08/19/2025. He acquired 5,000 shares of common stock at $19.95 and sold 5,000 shares at $36, leaving him with 34,374 shares of common stock beneficially owned after the transactions. On the same date he was reported as acquiring a non-qualified stock option covering 5,000 shares with an exercise price of $19.95, reflecting a post-transaction total of 40,000 options. The filing notes these options were originally granted on November 11, 2016 and vest 25% after one year with the remainder vesting monthly over the following three years. The Form 4 is signed by Mr. Wehrwein on 08/21/2025.

Positive

• Transparency: Disclosure includes exact transaction dates, prices, and post-transaction beneficial ownership counts.
• Option detail provided: Original grant date and vesting schedule for the options are stated, aiding clarity on exercisability.

Negative

• Net common shares decreased: Beneficial ownership of common stock fell from 39,374 to 34,374 after the reported transactions.

Insights

Securities Analyst

TL;DR: Director executed same-day buy and sell of 5,000 shares and added 5,000 option rights; net common holdings declined by 5,000 shares.

From a disclosure and market-impact standpoint, this Form 4 documents contemporaneous acquisition and disposition activity by an insider. The reported transactions are precise: an open-market purchase at $19.95 and a sale at $36 for equal share counts, leaving the reporting person with 34,374 common shares. Additionally, acquisition of a non-qualified option for 5,000 shares at $19.95 increases option holdings to 40,000. These are routine Section 16 disclosures that provide transparency on executive ownership and option positions but do not by themselves reveal company performance or strategy.

Corporate Governance Expert

TL;DR: Form 4 properly discloses mixed transactions and option holdings; documentation shows vesting schedule from 2016 grant.

The filing includes the required details: transaction codes, prices, resulting beneficial ownership, and an explanation of the original option grant and vesting cadence. For governance review, the simultaneous buy and sell and the option increase are notable for record-keeping and potential insider trading policy review, but the filing contains no indication of policy breaches or material corporate actions.

Insider Trade Summary

Net Seller: 5,000 shares ($180,000)

Net Sell 3 txns

Insider WEHRWEIN SVEN

Role Director

Sold 5,000 shs ($180K)

Type	Security	Shares	Price	Value
Exercise	Non-qualified Stock Option (right to buy)	5,000	$0.00	--
Exercise	Common Stock	5,000	$19.95	$100K
Sale	Common Stock	5,000	$36.00	$180K

Holdings After Transaction: Non-qualified Stock Option (right to buy) — 40,000 shares (Direct); Common Stock — 39,374 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WEHRWEIN SVEN

(Last) (First) (Middle)

4877 EAST LAKE HARRIET PARKWAY

(Street)

MINNEAPOLIS MN 55419

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2025		M		5,000	A	$19.95	39,374	D
Common Stock	08/19/2025		S		5,000	D	$36	34,374	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-qualified Stock Option (right to buy)	$19.95	08/19/2025		M			5,000	11/11/2017(1)	11/11/2026	Non-qualified Stock Option (right to buy)	5,000	$0	40,000	D

Explanation of Responses:

1. These options were granted on November 11, 2016. These options vest and are exercisable as to 25% of the shares one year from the date of grant and the remaining 75% thereafter vests and are exercisable in equal monthly installments on the same day of the month over the following three years.

Remarks:

	/s/ Sven Wehrwein	08/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did AtriCure director Sven Wehrwein report on Form 4 (ATRC)?

He reported buying 5,000 common shares at $19.95 and selling 5,000 shares at $36 on 08/19/2025, and acquiring a non-qualified option for 5,000 shares at $19.95.

How many shares of ATRC does Sven Wehrwein beneficially own after these transactions?

The Form 4 reports he beneficially owns 34,374 common shares following the reported transactions.

What is the post-transaction count of stock options reported by Sven Wehrwein?

Following the reported option acquisition, the filing shows he beneficially owns 40,000 non-qualified stock options.

When were the reported stock options originally granted and what is their vesting schedule?

The options were granted on November 11, 2016; they vest 25% after one year and the remaining 75% vest in equal monthly installments over the next three years.

What prices were reported for the stock purchase and sale on 08/19/2025?

The purchase price was $19.95 and the sale price was $36.00.